在标准和酸性条件下，新型 pH 激活氟喹诺酮类药物法氟沙星的体外活性谱。
In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
机构信息
MerLion Pharmaceuticals GmbH, Robert-Rössle Strasse 10, Berlin, Germany.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7. doi: 10.1128/AAC.00833-10. Epub 2011 Jun 27.
Abstract
Finafloxacin is a novel fluoroquinolone that exhibits enhanced antibacterial activity under acidic conditions. The aim of this study was to define the in vitro pH-activity relationship. Finafloxacin exhibited optimal antibacterial activity between pH 5.0 and 6.0 at which MICs were 4- to 8-fold lower than those determined at neutral pH. These observations were then confirmed against a larger collection of bacteria. These data suggest that finafloxacin could potentially offer a therapeutic advantage within acidic foci of infection.
摘要
菲那沙星是一种新型氟喹诺酮类药物，在酸性条件下表现出增强的抗菌活性。本研究旨在确定体外 pH-活性关系。菲那沙星在 pH5.0 到 6.0 之间表现出最佳的抗菌活性，此时 MIC 比在中性 pH 时低 4 到 8 倍。这些观察结果随后在更大的细菌集合中得到了证实。这些数据表明，菲那沙星在感染的酸性病灶内可能具有潜在的治疗优势。
相似文献
1
In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.在标准和酸性条件下，新型 pH 激活氟喹诺酮类药物法氟沙星的体外活性谱。
Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7. doi: 10.1128/AAC.00833-10. Epub 2011 Jun 27.
2
Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.新型氟喹诺酮类药物法氟沙星在酸性 pH 值下具有增强的活性，对金黄色葡萄球菌、单核细胞增生李斯特菌和嗜肺军团菌的细胞外和细胞内活性。
Int J Antimicrob Agents. 2011 Jul;38(1):52-9. doi: 10.1016/j.ijantimicag.2011.03.002. Epub 2011 May 18.
3
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.研究氟喹诺酮类药物非那沙星对环丙沙星敏感和耐药鲍曼不动杆菌分离株的活性。
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5. doi: 10.1128/AAC.01637-09. Epub 2010 Jan 25.
4
Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.证明新型氟喹诺酮类药物非那沙星对吸入伯克霍尔德菌（类鼻疽杆菌）的防护效果。
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00082-17. Print 2017 Jul.
5
Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.法氟沙星对表现为正常菌落形态和小菌落变异表型的葡萄球菌的体外比较活性。
J Antimicrob Chemother. 2011 Dec;66(12):2809-13. doi: 10.1093/jac/dkr393. Epub 2011 Sep 21.
6
Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.尿液基质和 pH 值对达托霉素和环丙沙星对泌尿生殖道大肠埃希菌和肺炎克雷伯菌的效力的影响。
J Urol. 2015 Aug;194(2):563-70. doi: 10.1016/j.juro.2015.01.094. Epub 2015 Jan 29.
7
Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.不同 pH 条件下非那沙星对表达不同氟喹诺酮耐药机制组合的同源大肠埃希菌的抗菌活性。
J Antimicrob Chemother. 2010 Dec;65(12):2530-3. doi: 10.1093/jac/dkq375. Epub 2010 Oct 12.
8
Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes.pH 值对法非诺沙星对胞外和胞内的唐菖蒲伯克霍尔德菌、假结核耶尔森菌和嗜吞噬细胞无形体的活性以及其在 THP-1 单核细胞中的细胞药代动力学的影响。
Clin Microbiol Infect. 2020 Sep;26(9):1254.e1-1254.e8. doi: 10.1016/j.cmi.2019.07.028. Epub 2019 Aug 9.
9
10
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.采用间断时间序列分析来评估氟喹诺酮类药物处方集的变化与革兰氏阴性病原体易感性及耐甲氧西林金黄色葡萄球菌分离率之间的关联。
Antimicrob Agents Chemother. 2006 Jun;50(6):2106-12. doi: 10.1128/AAC.01359-05.
引用本文的文献
1
An evaluation of antibiotic options for the treatment of biothreat pathogens.用于治疗生物威胁病原体的抗生素选择评估。
Front Antibiot. 2025 Aug 14;4:1611588. doi: 10.3389/frabi.2025.1611588. eCollection 2025.
2
liver abscesses: pathogenesis, treatment, and ongoing challenges.肝脓肿：发病机制、治疗及当前挑战
Infect Immun. 2025 Aug 12;93(8):e0050824. doi: 10.1128/iai.00508-24. Epub 2025 Jul 3.
3
Layering vaccination with antibiotic therapy results in protection and clearance of in Balb/c mice.在Balb/c小鼠中，将疫苗接种与抗生素治疗分层可实现保护和清除。
Infect Immun. 2024 Mar 12;92(3):e0045523. doi: 10.1128/iai.00455-23. Epub 2024 Jan 30.
4
Exploitation of microbial activities at low pH to enhance planetary health.利用微生物在低 pH 值下的活性来增强行星健康。
FEMS Microbiol Rev. 2024 Jan 12;48(1). doi: 10.1093/femsre/fuad062.
5
Comparison of the antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against strains isolated in China.氧氟沙星、左氧氟沙星、莫西沙星、西他沙星、非那沙星和德拉氟沙星对中国分离菌株的抗菌活性比较。
Heliyon. 2023 Oct 30;9(11):e21216. doi: 10.1016/j.heliyon.2023.e21216. eCollection 2023 Nov.
6
Activity of Finafloxacin against Panels of Respiratory Pathogens.非奈利酮对呼吸道病原体组的活性。
Antibiotics (Basel). 2023 Jun 23;12(7):1096. doi: 10.3390/antibiotics12071096.
7
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.近二十年获批上市的抗生素概述：回顾与展望。
Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.
8
Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.对抗抗生素耐药性——寻找新抗菌药物的策略和（临床前）研发。
EMBO Rep. 2023 Jan 9;24(1):e56033. doi: 10.15252/embr.202256033. Epub 2022 Dec 19.
9
Efficacy of finafloxacin in a murine model of inhalational glanders.非那沙星在吸入性鼻疽小鼠模型中的疗效
Front Microbiol. 2022 Nov 24;13:1057202. doi: 10.3389/fmicb.2022.1057202. eCollection 2022.
10
An Investigation into the Re-Emergence of Disease Following Cessation of Antibiotic Treatment in Balb/c Mice Infected with Inhalational .对感染吸入性病菌的Balb/c小鼠停止抗生素治疗后疾病再次出现的调查
Antibiotics (Basel). 2022 Oct 20;11(10):1442. doi: 10.3390/antibiotics11101442.
本文引用的文献
1
Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine.新型抗菌药 finafloxacin 对 Mueller-Hinton 肉汤和合成尿中测试的部分革兰氏阳性和革兰氏阴性细菌的体外比较活性。
Antimicrob Agents Chemother. 2011 Apr;55(4):1814-8. doi: 10.1128/AAC.00886-10. Epub 2011 Jan 18.
2
Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.不同 pH 条件下非那沙星对表达不同氟喹诺酮耐药机制组合的同源大肠埃希菌的抗菌活性。
J Antimicrob Chemother. 2010 Dec;65(12):2530-3. doi: 10.1093/jac/dkq375. Epub 2010 Oct 12.
3
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.研究氟喹诺酮类药物非那沙星对环丙沙星敏感和耐药鲍曼不动杆菌分离株的活性。
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5. doi: 10.1128/AAC.01637-09. Epub 2010 Jan 25.
4
Hyperinflammation in airways of cystic fibrosis patients: what's new?囊性纤维化患者气道中的过度炎症：有何新进展？
Expert Rev Mol Diagn. 2008 Jul;8(4):359-63. doi: 10.1586/14737159.8.4.359.
5
Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide.pH对氟喹诺酮类、大环内酯类和酮内酯类药物体外活性及耐药性产生倾向的影响。
Infection. 2005 Dec;33 Suppl 2:36-43. doi: 10.1007/s15010-005-8206-y.
6
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.在囊性纤维化气道条件下，酸化亚硝酸盐衍生物对黏液型铜绿假单胞菌的厌氧杀伤作用。
J Clin Invest. 2006 Feb;116(2):436-46. doi: 10.1172/JCI24684. Epub 2006 Jan 26.
7
Antimicrobial safety: focus on fluoroquinolones.抗菌药物安全性：聚焦氟喹诺酮类药物
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57. doi: 10.1086/428055.
8
Conditions affecting the results of susceptibility testing for the quinolone compounds.
Chemotherapy. 1988;34(4):308-14. doi: 10.1159/000238584.
Zotero 插件